Drug intelligence / Profile preview

intravenous lipid emulsion comprised of fish oil (omega-3-acid triglycerides)

Development stage
Approved
Lead developer
Fresenius Kabi
Modality
Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Intravenous lipid emulsion comprised of fish oil, primarily known by the brand name Omegaven, is a specialized parenteral nutrition product composed of 100% fish oil triglycerides. It is rich in long-chain omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Unlike traditional soybean oil-based emulsions, which are high in pro-inflammatory omega-6 fatty acids and phytosterols, fish oil emulsions exert anti-inflammatory effects by shifting the production of eicosanoids toward less inflammatory series and by activating peroxisome proliferator-activated receptors (PPARs). Its primary clinical indication is the treatment of parenteral nutrition-associated liver disease (PNALD) and intestinal failure-associated liver disease (IFALD) in pediatric patients, where it has been shown to reverse cholestasis and improve liver function. It provides essential fatty acids and energy as part of a parenteral nutrition regimen when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Brand names
Omegaven
Other names
fish oil triglyceridesintravenous fish oil emulsionFOLEfish oil lipid emulsion
02

Targets

FFAR1 (Free fatty acid receptor 1)FFAR4 (Free fatty acid receptor 4)PPARG (Peroxisome proliferator-activated receptor gamma)ALOX5 (Arachidonate 5-lipoxygenase)PPARA (Peroxisome proliferator-activated receptor alpha)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on intravenous lipid emulsion comprised of fish oil (omega-3-acid triglycerides).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on intravenous lipid emulsion comprised of fish oil (omega-3-acid triglycerides).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call